SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff, amplified by SOXLs 3x daily leverage, has fueled attention; LAM Researchs warning about component supply constraints added to concerns around AI-chip demand and heavy AI spending. Traders are divided between viewing the drop as an oversold washout and expecting further losses, while debating whether semiconductor and AI growth remains intact or is being repriced.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Mercks Keytruda, released after a data leak, are driving attention: traders note the results showed lower recurrence risk but argue they fell short of expectations built into the stocks steep run-up, prompting a sharp selloff. The community is split between viewing the drop as a sell-the-news overreaction to positive data and seeing it as a valuation reset, with intense debate over the vaccines commercial potential and the stocks next move.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised full-year outlook were met with a sharp selloff, with traders debating whether heavy capital spending, negative cash flow and a rich valuation outweigh the companys growth prospects. Some blame broader pressure on AI-related stocks, while bullish traders view the decline as an overreaction to results they consider strong.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

A steep pullback from recent highs is dominating discussion, with traders pointing to broader market and sector selling alongside higher oil and jet-fuel costs amid Middle East tensions. Some see the companys fundamentals and share buybacks as reasons to stay bullish, while others question the weakness and warn of further downside.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPEs sharp rebound and gains alongside a broader meme-coin rally are driving attention, with traders cheering for another leg higher. Others question the moves staying power, pointing to thin volume, repeated resistance, and choppy consolidation; no specific news catalyst is established.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers quarterly update has drawn attention after revenue missed expectations and management cut its sales outlook amid price-conscious shoppers and heavier footwear promotions, despite raising earnings guidance. Traders are divided between viewing the selloff as an overreaction given profitability and buybacks, and focusing on weaker growth and the cautious outlook.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp selloff and fresh lows are being tied by traders to plans to explore a separate listing for fintech unit Monee and launch Sea Cloud, raising concerns about spending, execution and how a listing could affect existing shareholders. Some see Monee as a source of potential value, while others view the plans as added uncertainty amid a severe technical downturn.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Bullish analyst initiations are drawing attention to Celcuitys commercial opportunity for FDA-approved REVTORPYK, with traders also highlighting a potential PIK3CA-mutant label expansion. Optimism about the drugs market potential is balanced by debate over whether the early launch can translate into meaningful prescription and revenue growth.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductor stocks are under pressure after LAM Researchs CEO warned that component supply constraints could persist into 2027, prompting a broad chip-sector selloff. Traders are split between viewing the decline and tests of key support as an oversold buying opportunity and warning that weakening AI sentiment and continued lower highs point to more downside.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat outlook were met with a sharp share decline, prompting traders to debate whether the selloff reflects a broader retreat from AI-linked stocks or concerns about higher capital spending and a potentially cyclical peak outweighing robust storage demand. Some see the reaction as an overdone sell-the-news move, while others question how durable current growth and pricing will be.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Turning Towards Momentum Narratives

Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced significant regulatory, scientific, and strategic developments. $NTHI, $ERNA, $VIVS, $LLY, $VEEE, $SOBR

Ernexa Scores Independent Validation Before High-Stakes Human Cancer Therapy Trials

Ernexa Therapeutics (NASDAQ:ERNA) has taken a notable step toward the clinic after announcing that an independent contract research organization successfully reproduced the preclinical efficacy of its lead cell therapy candidate, ERNA-101, in ovarian cancer models. Independent validation is closely watched in biotechnology because reproducibility can strengthen confidence in experimental findings before human testing begins.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million.
Catheter Precision (AMEX:VTAK)read more...

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.

Chasing the Next Explosive Small-Cap Run

Risk appetite came roaring back and several companies standing out, as market participants rotated heavily into sectors tied to transformative technologies and high-growth macro trends. $TGNT, $QUCY, $AEHL, $TDIC, $WGRX, $ERNA, $SLS, $WHWK

Ernexa Stock Is Jumping Today: What's Going On?

Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA 101 in ovarian cancer.read more...

ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts 

Equity

Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period.

Biotech’s Next Wave May Already be in Motion

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results

Ernexa’s ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models.

Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance...

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Ernexa Therapeutics, Inc. engages in the research and development of cellular therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. Its pipeline includes ERNA-101 (Ovarian Cancer) and ERNA-201 (Rheumatoid Arthritis). The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Loss per share narrowed to $6.95 from a loss of $57.76 per share last year.</li><li>Last week, the firm said its therapy completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models.</li><li>CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug application in the third quarter of 2026</li></ul>Shares of Ernexa Therapeutics Inc. (ERNA) extended their explosive rally on Tuesday, soaring more than 90% as investors piled into the biotech stock following a sharp narrowing of first-quarter losses and growing optimism around its promising ovarian cancer cell therapy program.Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period. The company also posted a sharp improvement in loss per share, which narrowed to $6.95 from $57.76 a year earlier.Trading in <a href="https://stocktwits.com/symbol/ERNA">ERNA shares</a> was halted seven times after the opening bell, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nyse.com/trade/trading-halts">according</a> to NYSE data.<h2 class="st-heading-2">Retail Can’t Stop Talking About ERNA’s Ovarian Cancer Trial Results</h2>Retail sentiment for ERNA shares on Stocktwits remained in the ‘extremely bullish’ territory, while message volumes increased by around 280% over a 24-hour period. ERNA was also among the top trending tickers on the platform.One user said the stock is a “long-term” investment, citing the trial update.<stembedurl>https://stocktwits.com/Alchemisttt/message/653084994</stembedurl>Another user said they were ‘hyper bullish’ about the trial results, but would not rule out a stock offering.<stembedurl>https://stocktwits.com/splitsoup/message/653083994</stembedurl><h2 class="st-heading-2">ERNA To File NDA BY Q3</h2>Last week, Ernexa <a href="https://stocktwits.com/news-articles/markets/equity/erna-stock-surged-ernexa-ovarian-cancer-trial/cZQzOzNReOK">said</a> its ERNA-101 therapy, combined with PD-1 immunotherapy, completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models, using mice. The therapy also boosted cancer-fighting immune activity and reduced tumor burden.In a letter to shareholders on Monday, CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug (IND) application in the third quarter (Q3) of 2026 and plans to begin a Phase 1 human trial later in the year.The stock has rallied nearly 250% since the pre-clinical trial results were reported.The company implemented a 1-for-25 reverse stock split earlier this month.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rigl-stock-jumps-short-interest-surges-to-record-high-why-is-retail-eyeing-a-further-upside/cZXXhLJReiW">RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$2.08
Prev Close	$2.11
Open	$2.10
Dividend Yield	0.00%
50-Day Moving Average	$3.58
Beta	0.93
Avg. Volume	47,918.34
PE Ratio	-0.11

52-Week High	$71.50
52-Week Low	$1.84
Market Capitalization	$3.39M
EPS (Annual)	-$55.89
Price to Book	0.76
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

ERNA Fundamentals